Journal article
A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group
Abstract
Purpose: To define the maximum tolerated dose (MTD), the dose limiting toxicity (DLT), the biological active (BA) dose and the pharmacokinetics (PK) of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa™) when administered continuously as a once daily dose in patients with advanced, incurable solid tumours. Patients and methods: Twenty-eight patients were enrolled in cohorts of three from three National Cancer …
Authors
Goss G; Hirte H; Miller WH; Lorimer IAJ; Stewart D; Batist G; Parolin DAE; Hanna P; Stafford S; Friedmann J
Journal
Investigational New Drugs, Vol. 23, No. 2, pp. 147–155
Publisher
Springer Nature
Publication Date
January 2005
DOI
10.1007/s10637-005-5860-y
ISSN
0167-6997